Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 272

1.

Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings.

Guerci B, Charbonnel B, Gourdy P, Hadjadj S, Hanaire H, Marre M, Vergès B.

Diabetes Metab. 2019 Jan 21. pii: S1262-3636(19)30021-7. doi: 10.1016/j.diabet.2019.01.006. [Epub ahead of print] Review.

PMID:
30677504
2.

Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.

Gallo S, Charbonnel B, Goldman A, Shi H, Huyck S, Darekar A, Lauring B, Terra SG.

Diabetes Obes Metab. 2019 Jan 7. doi: 10.1111/dom.13631. [Epub ahead of print]

PMID:
30614616
3.

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes.

Yale JF, Aroda VR, Charbonnel B, Sinclair AJ, Trescoli C, Cahn A, Bigot G, Merino-Trigo A, Brulle-Wohlhueter C, Bolli GB, Ritzel R.

Diabetes Metab. 2018 Oct 23. pii: S1262-3636(18)30196-4. doi: 10.1016/j.diabet.2018.10.002. [Epub ahead of print]

4.

Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).

Cannon CP, McGuire DK, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Charbonnel B, Shih WJ, Gallo S, Masiukiewicz U, Golm G, Cosentino F, Lauring B, Terra SG; VERTIS-CV Investigators.

Am Heart J. 2018 Dec;206:11-23. doi: 10.1016/j.ahj.2018.08.016. Epub 2018 Sep 5.

5.

Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis.

Charbonnel B, Simon D, Dallongeville J, Bureau I, Dejager S, Levy-Bachelot L, Gourmelen J, Detournay B.

Pharmacoecon Open. 2018 Jun;2(2):209-219. doi: 10.1007/s41669-017-0050-3.

6.

The Use of Saxagliptin in People with Type 2 Diabetes in France: The Diapazon Epidemiological Study.

Balkau B, Charbonnel B, Penfornis A, Chraibi N, Lahouegue A, Faure C, Thomas-Delecourt F, Detournay B.

Diabetes Ther. 2017 Oct;8(5):1147-1162. doi: 10.1007/s13300-017-0311-2. Epub 2017 Sep 25.

7.

Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).

Rosenstock J, Frias J, Páll D, Charbonnel B, Pascu R, Saur D, Darekar A, Huyck S, Shi H, Lauring B, Terra SG.

Diabetes Obes Metab. 2018 Mar;20(3):520-529. doi: 10.1111/dom.13103. Epub 2017 Oct 2. Erratum in: Diabetes Obes Metab. 2018 Nov;20(11):2708.

PMID:
28857451
8.

Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany.

Khunti K, Godec TR, Medina J, Garcia-Alvarez L, Hiller J, Gomes MB, Cid-Ruzafa J, Charbonnel B, Fenici P, Hammar N, Hashigami K, Kosiborod M, Nicolucci A, Shestakova MV, Ji L, Pocock S.

Diabetes Obes Metab. 2018 Feb;20(2):389-399. doi: 10.1111/dom.13083. Epub 2017 Sep 28.

9.

Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program.

Ji L, Bonnet F, Charbonnel B, Gomes MB, Kosiborod M, Khunti K, Nicolucci A, Pocock S, Rathmann W, Shestakova MV, Shimomura I, Watada H, Fenici P, Hammar N, Hashigami K, Macaraeg G, Surmont F, Medina J.

J Diabetes Complications. 2017 Jul;31(7):1188-1196. doi: 10.1016/j.jdiacomp.2017.03.011. Epub 2017 Apr 5.

10.

Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes.

Owens DR, Bolli GB, Charbonnel B, Haak T, Landgraf W, Porcellati F, Traylor L, Kautzky-Willer A.

Diabetes Obes Metab. 2017 Nov;19(11):1546-1554. doi: 10.1111/dom.12966. Epub 2017 Jul 27.

PMID:
28449412
11.

After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?

Vergès B, Charbonnel B.

Diabetes Metab. 2017 Apr;43 Suppl 1:2S3-2S12. doi: 10.1016/S1262-3636(17)30067-8. Review.

PMID:
28431669
12.

Predicting severe hypoglycaemia with self-monitoring of blood glucose in type 1 diabetes.

Moutairou A, Roussel R, Charbonnel B, Leye A, Detournay B, Mohammedi K, Potier L.

Diabetes Metab. 2017 Sep;43(4):392-394. doi: 10.1016/j.diabet.2016.11.009. Epub 2017 Feb 1. No abstract available.

PMID:
28161368
13.

[Determinants of the cost of initiation of insulin therapy type 2 diabetic patients in France: possible approaches to optimization].

Hanaire H, Attali C, Lecointre B, Fraysse M, Gouet D, Babel MR, Charbonnel B, Sarkozy F, Gourmelen J, Detournay B.

Sante Publique. 2016 Dec 19;28(6):781-789. French.

PMID:
28155773
14.

Short-term effect of severe hypoglycaemia on glycaemic control in the Diabetes Control and Complications Trial.

Moutairou A, Roussel R, Charbonnel B, El Boustany R, Nicolas A, Leye A, Mohammedi K, Marre M, Detournay B, Potier L.

Diabetes Metab. 2017 Apr;43(2):187-190. doi: 10.1016/j.diabet.2016.08.001. Epub 2016 Sep 21. No abstract available.

PMID:
27665052
15.

Persistence with Insulin Therapy in Patients with Type 2 Diabetes in France: An Insurance Claims Study.

Roussel R, Charbonnel B, Behar M, Gourmelen J, Emery C, Detournay B.

Diabetes Ther. 2016 Sep;7(3):537-49. doi: 10.1007/s13300-016-0185-8. Epub 2016 Jul 15.

16.

Which oral antidiabetic drug to combine with metformin to minimize the risk of hypoglycemia when initiating basal insulin?: A randomized controlled trial of a DPP4 inhibitor versus insulin secretagogues.

Gautier JF, Monguillon P, Verier-Mine O, Valensi P, Fiquet B, Dejager S, Charbonnel B.

Diabetes Res Clin Pract. 2016 Jun;116:26-8. doi: 10.1016/j.diabres.2016.04.008. Epub 2016 Apr 23.

PMID:
27321312
17.

Sotagliflozin as a potential treatment for type 2 diabetes mellitus.

Cariou B, Charbonnel B.

Expert Opin Investig Drugs. 2015;24(12):1647-56. doi: 10.1517/13543784.2015.1100361. Epub 2015 Nov 7. Review.

PMID:
26548423
18.

Cost of Type 2 Diabetes According to Glucose-Lowering Medications in France.

Charbonnel B, Dallongeville J, Simon D, Bureau I, Leproust S, Levy-Bachelot L, Gourmelen J, Detournay B.

Value Health. 2015 Nov;18(7):A604. doi: 10.1016/j.jval.2015.09.2079. Epub 2015 Oct 20. No abstract available.

19.

Patterns of Pharmacological Treatment in Type 2 Diabetes in France in 2013.

Simon D, Dallongeville J, Charbonnel B, Bureau I, Detournay B, Leproust S, Levy-Bachelot L, Gourmelen J.

Value Health. 2015 Nov;18(7):A599. doi: 10.1016/j.jval.2015.09.2054. Epub 2015 Oct 20. No abstract available.

20.

Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.

Barnett AH, Charbonnel B, Moses RG, Kalra S.

Curr Med Res Opin. 2015;31(10):1919-31. doi: 10.1185/03007995.2015.1081589. Epub 2015 Sep 11. Review.

PMID:
26361231
21.

Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: results from the DIALOG study.

Cariou B, Fontaine P, Eschwege E, Lièvre M, Gouet D, Huet D, Madani S, Lavigne S, Charbonnel B.

Diabetes Metab. 2015 Apr;41(2):116-25. doi: 10.1016/j.diabet.2014.10.007. Epub 2014 Nov 24.

PMID:
25465273
22.

Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.

D'Alessio D, Häring HU, Charbonnel B, de Pablos-Velasco P, Candelas C, Dain MP, Vincent M, Pilorget V, Yki-Järvinen H; EAGLE Investigators.

Diabetes Obes Metab. 2015 Feb;17(2):170-8. doi: 10.1111/dom.12406. Epub 2014 Dec 7.

PMID:
25359159
23.

Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis.

Charbonnel B, Bertolini M, Tinahones FJ, Domingo MP, Davies M.

J Diabetes Complications. 2014 Nov-Dec;28(6):880-6. doi: 10.1016/j.jdiacomp.2014.07.007. Epub 2014 Jul 18.

24.

Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal.

Scheen AJ, Charbonnel B.

Diabetes Metab. 2014 Jun;40(3):176-85. doi: 10.1016/j.diabet.2014.03.004. Epub 2014 Apr 30. Review.

25.

Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.

Shen L, Shah BR, Reyes EM, Thomas L, Wojdyla D, Diem P, Leiter LA, Charbonnel B, Mareev V, Horton ES, Haffner SM, Soska V, Holman R, Bethel MA, Schaper F, Sun JL, McMurray JJ, Califf RM, Krum H.

BMJ. 2013 Dec 9;347:f6745. doi: 10.1136/bmj.f6745. Erratum in: BMJ. 2014;348:f1339.

26.

Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.

Barnett AH, Charbonnel B, Li J, Donovan M, Fleming D, Iqbal N.

Clin Drug Investig. 2013 Oct;33(10):707-17. doi: 10.1007/s40261-013-0107-8.

PMID:
23949898
27.

Risk of breast cancer by individual insulin use: an international multicenter study.

Grimaldi-Bensouda L, Cameron D, Marty M, Barnett AH, Penault-Llorca F, Pollak M, Charbonnel B, Riddle M, Mignot L, Boivin JF, Khachatryan A, Rossignol M, Bénichou J, Alpérovitch A, Abenhaim L; ISICA Group.

Diabetes Care. 2014;37(1):134-43. doi: 10.2337/dc13-0695. Epub 2013 Aug 15.

PMID:
23949559
28.

A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment.

Gastaldelli A, Balas B, Ratner R, Rosenstock J, Charbonnel B, Bolli GB, Boldrin M, Balena R.

Diabetes Obes Metab. 2014 Feb;16(2):170-8. doi: 10.1111/dom.12192. Epub 2013 Aug 22.

PMID:
23911196
29.

Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?

Charbonnel B, Schweizer A, Dejager S.

Hosp Pract (1995). 2013 Apr;41(2):93-107. doi: 10.3810/hp.2013.04.1059. Review.

PMID:
23680741
30.

Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.

Charbonnel B, Steinberg H, Eymard E, Xu L, Thakkar P, Prabhu V, Davies MJ, Engel SS.

Diabetologia. 2013 Jul;56(7):1503-11. doi: 10.1007/s00125-013-2905-1. Epub 2013 Apr 19.

PMID:
23604551
31.

The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial.

Rosenstock J, Balas B, Charbonnel B, Bolli GB, Boldrin M, Ratner R, Balena R; T-emerge 2 Study Group.

Diabetes Care. 2013 Mar;36(3):498-504. doi: 10.2337/dc12-0709. Epub 2012 Nov 8.

32.

Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study.

Hermans MP, Delibasi T, Farmer I, Lohm L, Maheux P, Piatti P, Malvolti E, Jörgens S, Charbonnel B.

Curr Med Res Opin. 2012 Oct;28(10):1635-45. doi: 10.1185/03007995.2012.735646. Epub 2012 Oct 12.

PMID:
23020253
33.

Intensification of polypharmacy glucose-lowering treatment in type-2 diabetes: when to be cautious?

Charbonnel B.

Diabetes Res Clin Pract. 2012 Jul;97(1):3-5. doi: 10.1016/j.diabres.2012.05.008. Epub 2012 Jun 4. No abstract available.

PMID:
22672881
34.

Thiazolidinediones and PPARγ agonists: time for a reassessment.

Cariou B, Charbonnel B, Staels B.

Trends Endocrinol Metab. 2012 May;23(5):205-15. doi: 10.1016/j.tem.2012.03.001. Epub 2012 Apr 17. Review.

PMID:
22513163
35.

Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.

Barnett AH, Charbonnel B, Donovan M, Fleming D, Chen R.

Curr Med Res Opin. 2012 Apr;28(4):513-23. doi: 10.1185/03007995.2012.665046. Epub 2012 Mar 1.

PMID:
22313154
36.

Insulin therapy for diabetes mellitus: treatment regimens and associated costs.

Charbonnel B, Penfornis A, Varroud-Vial M, Kusnik-Joinville O, Detournay B.

Diabetes Metab. 2012 Apr;38(2):156-63. doi: 10.1016/j.diabet.2011.10.003. Epub 2011 Dec 14.

PMID:
22172400
37.

[Sugar-sweetened beverages and cardiometabolic risk].

Dallongeville J, Charbonnel B, Desprès JP.

Presse Med. 2011 Oct;40(10):910-5. doi: 10.1016/j.lpm.2011.02.042. Epub 2011 Jun 17. French.

PMID:
21684105
38.

High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive.

Ferrannini E, Betteridge DJ, Dormandy JA, Charbonnel B, Wilcox RG, Spanheimer R, Erdmann E, Defronzo RA, Laakso M.

Diabetes Obes Metab. 2011 Aug;13(8):759-64. doi: 10.1111/j.1463-1326.2011.01404.x.

PMID:
21457426
39.

Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes.

Bolli GB, Luzio S, Marzotti S, Porcellati F, Sert-Langeron C, Charbonnel B, Zair Y, Owens DR.

Diabetes Obes Metab. 2011 Mar;13(3):251-7. doi: 10.1111/j.1463-1326.2010.01343.x.

40.

Pharmacological management of type 2 diabetes: the potential of incretin-based therapies.

Charbonnel B, Cariou B.

Diabetes Obes Metab. 2011 Feb;13(2):99-117. doi: 10.1111/j.1463-1326.2010.01317.x. Review.

PMID:
21199262
41.
42.

The international study of insulin and cancer.

Grimaldi-Bensouda L, Marty M, Pollak M, Cameron D, Riddle M, Charbonnel B, Barnett AH, Boffetta P, Boivin JF, Evans M, Rossignol M, Benichou J, Abenhaim L; ISICA group.

Lancet. 2010 Sep 4;376(9743):769-70. doi: 10.1016/S0140-6736(10)61374-8. No abstract available. Erratum in: Lancet. 2010 Oct 16;376(9749):1302.

PMID:
20816540
43.

Thiazolidinediones and cardiovascular risk - a question of balance.

Erdmann E, Charbonnel B, Wilcox R.

Curr Cardiol Rev. 2009 Aug;5(3):155-65. doi: 10.2174/157340309788970333.

44.

[Is the metabolic syndrome still a useful entity?].

Charbonnel B.

Rev Prat. 2010 Apr 20;60(4):478-84. French.

PMID:
20465120
45.

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis.

Schernthaner G, Barnett AH, Betteridge DJ, Carmena R, Ceriello A, Charbonnel B, Hanefeld M, Lehmann R, Malecki MT, Nesto R, Pirags V, Scheen A, Seufert J, Sjohölm A, Tsatsoulis A, DeFronzo R.

Diabetologia. 2010 Jul;53(7):1258-69. doi: 10.1007/s00125-010-1702-3. Epub 2010 Mar 31. Erratum in: Diabetologia. 2010 Aug;53(8):1813.

46.

Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19).

Charbonnel B, DeFronzo R, Davidson J, Schmitz O, Birkeland K, Pirags V, Scheen A; PROactive investigators.

J Clin Endocrinol Metab. 2010 May;95(5):2163-71. doi: 10.1210/jc.2009-1974. Epub 2010 Mar 17.

47.

Effect of valsartan on the incidence of diabetes and cardiovascular events.

NAVIGATOR Study Group, McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozár J, Califf RM.

N Engl J Med. 2010 Apr 22;362(16):1477-90. doi: 10.1056/NEJMoa1001121. Epub 2010 Mar 14. Erratum in: N Engl J Med. 2010 May 6;362(18):1748.

48.

Effect of nateglinide on the incidence of diabetes and cardiovascular events.

NAVIGATOR Study Group, Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozár J, Califf RM.

N Engl J Med. 2010 Apr 22;362(16):1463-76. doi: 10.1056/NEJMoa1001122. Epub 2010 Mar 14. Erratum in: N Engl J Med. 2010 May 6;362(18):1748.

49.

Clinical and metabolic characteristics of patients with latent autoimmune diabetes in adults (LADA): absence of rapid beta-cell loss in patients with tight metabolic control.

Chaillous L, Bouhanick B, Kerlan V, Mathieu E, Lecomte P, Ducluzeau PH, Delamaire M, Sonnet E, Maugendre D, Maréchaud R, Rohmer V, Saï P, Charbonnel B.

Diabetes Metab. 2010 Feb;36(1):64-70. doi: 10.1016/j.diabet.2009.07.004. Epub 2010 Jan 8.

PMID:
20060765
50.

Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18).

Scheen AJ, Tan MH, Betteridge DJ, Birkeland K, Schmitz O, Charbonnel B; PROactive investigators.

Diabet Med. 2009 Dec;26(12):1242-9. doi: 10.1111/j.1464-5491.2009.02857.x.

Supplemental Content

Loading ...
Support Center